Delving into the Latest Updates on Skin Prick Solution for Artemisia annua Pollen Allergens with Synapse

Overview

Basic Info

Drug Type

Allergen extract

Synonyms

Artemisia Annua Allergens (Zhejiang Wolwo Bio-Pharma), Artemisia annua pollen, 黄花蒿花粉变应原

+ [1]

Target-

Mechanism

Immunomodulators

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [1]

Active Indication

Rhinitis, Allergic, SeasonalAnaphylaxis

Inactive Indication

Allergic asthma

Originator Organization

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Active Organization

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (06 May 2023),

Rhinitis, Allergic, Seasonal

Regulation-

Login to view timeline

The sponsor hopes to conduct a multicenter, open-label clinical study to investigate the clinical efficacy and safety of Artemisia annua pollen allergen sublingual drops in adult patients with allergic rhinitis (or conjunctivitis) caused by Artemisia pollen, as well as the long-term efficacy for at least one pollen season after discontinuation of the drug.

Start Date15 Mar 2022

Sponsor / Collaborator

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

100 Clinical Results associated with Skin Prick Solution for Artemisia annua Pollen Allergens

Login to view more data

100 Translational Medicine associated with Skin Prick Solution for Artemisia annua Pollen Allergens

Login to view more data

100 Patents (Medical) associated with Skin Prick Solution for Artemisia annua Pollen Allergens

Login to view more data

30

Literatures (Medical) associated with Skin Prick Solution for Artemisia annua Pollen Allergens

01 Oct 2024·International Journal of Biological Macromolecules

Artemisia argyi polysaccharide alleviates osmotic diarrhea by enhancing intestinal barrier protection and anti-inflammation

Article

Author: Yang, Dexin ; Zeng, Changchun ; Sun, Huimin ; Zhang, Pengfei ; Hong, Weitao ; Xiao, Jiahai ; Xie, Qingqing

Artemisia argyi polysaccharide (AAP) is a homogeneous polysaccharide with a molecular weight of 16 kDa, displaying anti-inflammatory, antioxidant, and anti-tumorigenic properties, and potential protective effects on intestinal barrier function. It is anticipated to serve as an efficient component in diarrhea treatment. This study aims to examine the impact of AAP on diarrhea severity, intestinal barrier function, and inflammation in diarrhea-induced rats. The results demonstrated that AAP treatment notably decreased the incidence of diarrhea, reduced its severity, and lowered the disease activity score in rats, while also increasing body weight. Oral administration of AAP augmented goblet cell counts and elevated mucin-2 expression, aiding in the restoration of the mucus barrier. Additionally, AAP treatment enhanced colonic microbial diversity by increasing the abundance of S24-7 and Lactobacillus, while decreasing the levels of Bacteroides, Clostridium, and Sutterella. Moreover, the AAP administration elevated the levels of steroid hormones, prostaglandins, and their derivatives. By inhibiting the TLR4/MyD88/NF-κB pathway, AAP mitigated the release of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and increased the secretion of anti-inflammatory factor (IL-10). Overall, oral AAP administration effectively combats osmotic diarrhea by fortifying mucus barrier integrity and exerting anti-inflammatory effects, suggesting its potential use as an adjunctive agent in oral rehydration therapy.

01 Jun 2024·Veterinary World

The effects of Artemisia annua nutritional supplementation at varying concentrations on broiler growth, economic yield, and gene expression levels of certain antioxidant, inflammatory, and immune genes

Article

Author: El-Rayes, Talaat Khedr ; Baloza, Samar H. ; Elsokary, Mohamed M. M. ; Shehata, Seham F. ; Awad, Dina A. ; El-Keredy, Amira ; Mamdouh, Maha

Background and Aim: Artemisia annua (AA), used as a growth promoter in poultry, lowers feed costs and enhances economic efficiency. This study aimed to assess the impact of varying AA concentrations on broiler chicken growth, gene expression, and profitability. Materials and Methods: Two hundred 1-day-old male Cobb chicks were randomly allocated into four treatment groups, each containing five replicates and 10 birds. The experimental groups consisted of G1 (basal diet), G2 (basal diet with 0.3% AA), G3 (basal diet with 0.6% AA), and G4 (basal diet with 0.9% AA). The birds had continuous access to feed and water throughout the study. The experiment lasted for 42 days. we measured the growth performance (Feed intake, Life weight), carcass traits (weight after slaughter, dressed carcass, heart, gizzard, spleen, giblet and thymus weight), liver and spleen antioxidants (CAT, GSH, SOD), and gene expression of anti-inflammatory and immune- related genes. Results: The primary findings revealed that the addition of 0.6% AA had a positive impact (p < 0.05) on all investigated variables compared with the control and other groups. Dietary supplementation with 0.6% AA led to increased breast, giblet, skeleton, and total yield, and net return compared with the control group. Supplementation with AA exhibited antioxidant, anti-inflammatory, and immunological effects through improved levels of antioxidant superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) in tissue homogenates of the liver and spleen. It also upregulated the relative messenger RNA levels of anti-inflammatory interleukin (IL)-10, SOD, CAT, and GSH-Px, whereas IL-1β and tumor necrosis factor-alpha were downregulated. Conclusion: The study found that AA is a promising replacement for antibiotics in poultry farming as a growth promoter for chickens. 0.6% AA in the broiler diet yielded the best results, striking a balance between superior performance and robust economic benefits. Keywords: Artemisia annua, broiler, carcass traits, economics, immunity, mRNA gene expression.

01 Jun 2023·3 Biotech

Evaluation of gene expression related to immunity, apoptosis, and gut integrity that underlies Artemisia's therapeutic effects in necrotic enteritis-challenged broilers.

Article

Author: El-Demerdash, Azza S ; Megahed, Hend M ; Ali, Naglaa M ; Mohamady, Sahar N

The experiment was designed to validate the effect of Artemisia annua and its novel commercial product (Navy Cox) on the control of necrotic enteritis (NE). A total of one hundred forty broiler chicks were randomly distributed into seven equal groups: G1, control negative; G2, infected with Eimeria (day 15) and C. perfringens (day 19); G3, treated with Navy Cox before challenge; G4, treated with Artemisia before challenge; G5, infected and then treated with Navy Cox; G6, infected and then treated with Artemisia; and G7, infected and treated with amoxicillin. Chicken response and immune organ indicants were recorded during the observation period (4 weeks). Whole blood and serum samples were collected for immunological evaluation, and tissue samples were collected for bacterial counts and estimation of mRNA expression of genes encoding apoptosis, tight junctions, and immunity. Chickens in the infected group revealed a significant decrease in RBCS, HB, PCV% total protein, Lysozyme, and nitric oxide activity in addition to leukocytosis, heterophilia, monocytosis, increase in cortisol, interleukins, and malondialdehyde. Treated groups displayed lower lesions, colony-forming units, and no mortality. Concurrently, a complete blood profile, antioxidants, and immune markers showed significant improvements. The mRNA expression levels of CASP, CLDN-1, OCLN, TJPI, MUC2, and cell-mediated immune response genes (p < 0.0001) were significantly alleviated in the treated groups compared with the challenged counterpart. This is the first-ever report on the efficacy valuation of Navy Cox compared to standard antibiotic treatment of clostridial NE. Navy Cox proved remarkable capability to minimize C. perfringens colonization in broiler intestines, modulation of mucus production, gut health integrity, immune organs, and immune response when used as a prophylactic agent in this form or naturally as Artemisia.

100 Deals associated with Skin Prick Solution for Artemisia annua Pollen Allergens

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Rhinitis, Allergic, Seasonal	CN	Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.	06 May 2023

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anaphylaxis	Phase 3	CN	Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.	11 Aug 2020
Allergic asthma	Phase 3	CN	Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.	21 Feb 2014